文献速递浆细胞疾病造血干细胞移植与细胞治疗

基于CRISPR的筛选揭示多发性骨髓瘤免疫治疗应答的决定因素

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
PubMed 文献 · Blood Adv · 2020-01-01

研究利用CRISPR干扰和CRISPR激活功能基因组学平台,系统鉴定控制多发性骨髓瘤免疫治疗抗原B细胞成熟抗原(BCMA)细胞表面表达的通路。发现HDAC7和Sec61复合物的药理学抑制可增加细胞表面BCMA(包括原代患者细胞),Sec61抑制增强BCMA靶向抗体药物偶联物的抗骨髓瘤疗效。CRISPR干扰嵌合抗原受体T细胞(CAR-T细胞)共培养筛选鉴定了控制骨髓瘤细胞对BCMA靶向CAR-T细胞应答的抗原依赖性和非抗原依赖性机制。

要点

  • HDAC7和Sec61复合物抑制增加多发性骨髓瘤细胞表面BCMA表达。
  • Sec61抑制增强BCMA靶向抗体药物偶联物的抗骨髓瘤疗效。
  • CRISPR干扰CAR-T共培养筛选鉴定抗原依赖和非依赖的应答机制。

核心结论

  • 本研究显示CRISPR筛选可揭示控制癌细胞对免疫治疗应答的机制,并提示潜在联合疗法。

研究设计与样本

  • 利用CRISPR干扰和CRISPR激活功能基因组学平台进行系统筛选。
  • 使用CRISPR干扰CAR-T细胞共培养筛选鉴定骨髓瘤细胞对BCMA靶向CAR-T细胞应答的机制。

主要发现

  • 药理学抑制HDAC7和Sec61复合物增加细胞表面BCMA,包括在原代患者细胞中。
  • 药理学抑制Sec61增强BCMA靶向抗体药物偶联物的抗骨髓瘤疗效。
  • CRISPR干扰CAR-T细胞共培养筛选鉴定了控制骨髓瘤细胞对BCMA靶向CAR-T细胞应答的抗原依赖性和抗原非依赖性机制。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer cells commonly develop resistance to immunotherapy by loss of antigen expression. Combinatorial treatments that increase levels of the target antigen on the surface of cancer cells have the potential to restore efficacy to immunotherapy. Here, we use our CRISPR interference- and CRISPR activation-based functional genomics platform to systematically identify pathways controlling cell surface expression of the multiple myeloma immunotherapy antigen B-cell maturation antigen (BCMA). We discovered that pharmacologic inhibition of HDAC7 and the Sec61 complex increased cell surface BCMA, including in primary patient cells. Pharmacologic Sec61 inhibition enhanced the antimyeloma efficacy of a BCMA-targeted antibody-drug conjugate. A CRISPR interference chimeric antigen receptor T cells (CAR-T cells) coculture screen enabled us to identify both antigen-dependent and antigen-independent mechanisms controlling response of myeloma cells to BCMA-targeted CAR-T cells. Thus, our study shows the potential of CRISPR screens to uncover mechanisms controlling response of cancer cells to immunotherapy and to suggest potential combination therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ramkumar P, Abarientos AB, Tian R, et al. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020. PMID: 32589729. doi:10.1182/bloodadvances.2019001346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。